Susan Desmond-Hellmann

Director at Pfizer

Current Senior Advisor and Board member of the Bill & Melinda Gates Medical Research Institute. Former Chief Executive Officer of the Bill & Melinda Gates Foundation from 2014 until 2020. Prior to joining the Bill & Melinda Gates Foundation, she was the first female and ninth overall Chancellor of the University of California, San Francisco (UCSF), from 2009 until 2014, where she still serves as an adjunct professor. From 1995 through 2009, Dr. Desmond-Hellmann was employed at Genentech where she served as President of Product Development from 2005 to 2009 overseeing pre-clinical and clinical development, business development and product portfolio management. Prior to joining Genentech, Dr. Desmond-Hellmann was Associate Director, Clinical Cancer Research at Bristol-Myers Squibb Pharmaceutical Research Institute. Director of Facebook Inc. from 2013 to 2019 and Procter & Gamble from 2010 to 2017. Pfizer Director since 2020. Member of our Governance & Sustainability Committee and Science and Technology Committee.


Org chart

This person is not in the org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Pfizer

606 followers

Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.